-
Feb 17, 2021
BRISBANE, Calif. --(BUSINESS WIRE)--Feb. 17, 2021-- Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, announced today that the Company has scheduled the release of its fourth quarter and full year 2020 financial results after the market closes on Wednesday, February 24, 2021 .
-
Feb 01, 2021
BRISBANE, Calif. --(BUSINESS WIRE)--Feb. 1, 2021-- Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, announced today the appointment of Rob Schott , MD, MPH, FACC, as Senior Vice President and Head of Development. Dr. Schott will lead clinical strategy across all phases of
-
Jan 06, 2021
BRISBANE, Calif. --(BUSINESS WIRE)--Jan. 6, 2021-- Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, announced today that Chief Financial Officer Sung Lee is leaving the Company to pursue a new opportunity overseas. Mr. Lee’s last day of employment will be February 1, 2021 .
-
Jan 05, 2021
BRISBANE, Calif. --(BUSINESS WIRE)--Jan. 5, 2021-- Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, announced today that management will present a corporate overview at the 39 th Annual J.P. Morgan Healthcare Conference on Wednesday, January 13 th at 5:20pm EST .